arrow
A

Ana Laura Ortega Granados

hospital universitario de jaén
H指数:29
被引数:3,726

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial

诱导化化疗免疫疗法后接化疗放疗和免疫疗法维持治疗在III期NSCLC(APOLO)中的研究:一项II期临床试验

2025-12-230
OAAI
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

增强型与标准皮肤管理联合阿曼曲妥珠单抗-拉泽替尼在EGFR突变型晚期NSCLC中的应用比较:COCOON全球随机对照试验

2025-09-090
OAAI
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain

肺癌幸存者中第二原发癌的发病率:按肿瘤学治疗的西班牙全国前瞻性队列研究

2025-08-120
OA
Corrigendum to “Clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient settings” [Current Problems in Cardiology 49(2024) 102239]

勘误: “oncology outpatient settings”中房颤且新诊断为肺癌患者的临床结局与死亡率 [Current Problems in Cardiology 49(2024) 102239]

2025-08-050
PRE
Biomarker landscape in advanced NSCLC: insights from a national prospective registry

晚期NSCLC中的生物标志物图谱:一项全国性前瞻性注册研究的见解

2025-07-280
PRE
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial

一项关于阿替利珠单抗、贝伐珠单抗和化疗在获得性耐药的EGFR突变非小细胞肺癌中的随机非对照II期研究——ETOP 15-19 ABC-lung试验

2025-04-010
PRE
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab

来自比较一线化疗加dodstarlimab或pembrolizumab的随机II期PERLA试验的转移性非鳞状非小细胞肺癌患者的患者报告结局

2024-11-010
OAAI
Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry
2024-10-010
OAAI
Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain

IMfirst研究中的分子特征分析:阿特珠单抗联合化疗治疗西班牙广泛期小细胞肺癌(ES-SCLC)

2024-09-010
PRE
CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment

关键:根据治疗方式分析西班牙胸肿瘤登记处的第二原发癌发生率

2024-09-010
PRE
Clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient settings
2024-02-012
PRE
Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients
2024-02-011
OA
Metabolomics signature as a survival predictor in patients with resectable colorectal liver metastasis
2024-01-181
OAAI
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial
2023-12-142
PRE
Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem plus pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
2023-10-010
OA
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

西班牙III期非小细胞肺癌患者的真实世界治疗模式和生存结果: 一项全国性队列研究

2023-10-018
OAAI